Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Sam Chun Dang Pharm. Co., Ltd

Capitalization 5,407B 3.62B 3.15B 2.86B 2.73B 4.96B 334B 5.14B 33.94B 13.49B 160B 13.59B 13.31B 577B P/E ratio 2023
-167x
P/E ratio 2024 -313x
Enterprise value 5,315B 3.56B 3.1B 2.81B 2.68B 4.87B 329B 5.05B 33.36B 13.26B 157B 13.36B 13.08B 567B EV / Sales 2023
8.93x
EV / Sales 2024 15.9x
Free-Float
61.54%
Yield 2023 *
-
Yield 2024 0.13%
Dec. 15 Sam Chun Dang Pharm. Co., Ltd announces Annual dividend CI
Nov. 14 Sam Chun Dang Pharm. Co., Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
25-10-22 Sam Chun Dang Pharm Co to buy 9.9 billion won worth of shares in Optus Pharmaceutical RE
25-10-21 OPTUS Pharmaceutical Co., Ltd. announced that it expects to receive KRW 9.999993888 billion in funding from Sam Chun Dang Pharm. Co., Ltd CI
25-09-18 Sam Chun Dang Pharm. Co., Ltd announced that it has received KRW 29.5419 billion in funding from Pureun Investment Inc., Shinhan Investment & Securities Co., Ltd. CI
25-08-27 Sam Chun Dang Pharm to divest 29.5 billion won worth of own shares RE
25-08-26 Sam Chun Dang Pharm. Co., Ltd announced that it expects to receive KRW 29.5419 billion in funding from Pureun Investment Inc., Shinhan Investment & Securities Co., Ltd. CI
25-08-14 Sam Chun Dang Pharm. Co., Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
25-05-15 Sam Chun Dang Pharm. Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-03-18 Sam Chun Dang Pharm. Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2024 CI
24-11-14 Sam Chun Dang Pharm. Co., Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
23-05-15 Sam Chun Dang Pharm. Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
21-02-25 Sam Chun Dang Pharm. Co., Ltd announced that it has received KRW 30 billion in funding from Korea Investment & Securities Co., Ltd., Investment Arm, NH Investment & Securities Co., Ltd., Investment Arm, KB Securities Co., Ltd., Investment Arm, and other investor CI
1 day-5.44%
1 week-4.82%
Current month-11.52%
1 month+36.45%
3 months+220.88%
6 months+235.63%
Current year+213.98%
1 week 720,000
Extreme 720000
819,000
1 month 544,000
Extreme 544000
860,000
Current year 232,500
Extreme 232500
860,000
1 year 127,600
Extreme 127600
860,000
3 years 49,750
Extreme 49750
860,000
5 years 26,100
Extreme 26100
860,000
10 years 8,380
Extreme 8380
860,000
Manager TitleAgeSince
Chief Executive Officer 52 2018-03-15
Corporate Officer/Principal 53 2022-03-28
Corporate Officer/Principal 57 2022-03-28
Director TitleAgeSince
Director/Board Member 52 2018-03-15
Director/Board Member 61 2021-03-22
Director/Board Member 57 2022-03-28
Change 5d. change 1-year change 3-years change Capi.($)
-5.44%-4.82%+281.40%+1,293.13% 11.97B
-1.02%-1.34%+5.93%+84.33% 46.73B
+1.55%+9.13%+44.19%+178.63% 36.39B
-1.12%-1.89%-11.07%+47.15% 11.48B
-2.10%-2.42%+0.43%+84.91% 9.86B
+5.65%+12.73%+79.18%+51.69% 8.47B
+0.87%+1.31%+38.10%+123.08% 7.98B
+1.30%-1.58%+43.15%-15.94% 6.96B
+0.22%+2.73%+54.82%+402.92% 6.62B
0.00%+4.30%+14.89%+60.87% 6.31B
Average -0.00%+0.38%+55.10%+231.08% 15.28B
Weighted average by Cap. -0.15%+1.76%+44.92%+207.25%

Financials

2023 2024
Net sales 193B 129M 112M 102M 97.09M 177M 11.91B 183M 1.21B 481M 5.7B 484M 474M 20.56B 211B 141M 123M 111M 106M 193M 13.04B 200M 1.32B 526M 6.24B 530M 519M 22.51B
Net income -10.38B -6.95M -6.06M -5.48M -5.23M -9.52M -642M -9.87M -65.17M -25.9M -307M -26.1M -25.55M -1.11B -10.92B -7.31M -6.37M -5.77M -5.5M -10.01M -675M -10.38M -68.52M -27.23M -323M -27.44M -26.86M -1.16B
Net Debt -39.12B -26.2M -22.82M -20.66M -19.71M -35.86M -2.42B -37.18M -246M -97.57M -1.16B -98.33M -96.25M -4.17B -91.98B -61.6M -53.66M -48.58M -46.35M -84.31M -5.69B -87.42M -577M -229M -2.72B -231M -226M -9.81B
Logo Sam Chun Dang Pharm. Co., Ltd
SAM CHUN DANG PHARM. CO., LTD is a Korea-based company mainly engaged in the manufacture of prescription medicines. The Company’s products portfolio consists of antibiotics used for treatment of sepsis, respiratory diseases and others; circulatory disease medicines including cardiovascular and endocrine medicaments used for treatment of diabetes, hypertension, angina and others under the brand names of Glilazide and Atenolol; digestive medicines used for treatment of duodenal ulcer, gastritis and others; ophthalmological agents used for treatment of conjunctivitis, keratitis and other eye inflammation under the brand names of Ofus and Toracin, and anti-inflammatories used to release postoperative pains under the brand name Barotase and others.
Employees
422
Date Price Change Volume
26-03-16 730,000.00 -5.44% 165,570
26-03-13 772,000.00 -1.91% 126,090
26-03-12 787,000.00 +1.68% 149,618
26-03-11 774,000.00 -1.53% 160,406
26-03-10 786,000.00 +2.48% 252,379
  1. Stock Market
  2. Equities
  3. A000250 Stock
SPRING SALE - 40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW